Shattuck Labs (NASDAQ:STTK) Now Covered by Analysts at BTIG Research

BTIG Research began coverage on shares of Shattuck Labs (NASDAQ:STTKGet Rating) in a research note published on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $12.00 price target on the stock.

Several other brokerages also recently issued reports on STTK. HC Wainwright restated a buy rating and set a $28.00 price objective on shares of Shattuck Labs in a research report on Friday, June 3rd. Citigroup assumed coverage on shares of Shattuck Labs in a research report on Wednesday, June 1st. They issued a buy rating and a $13.00 price target for the company. Finally, Needham & Company LLC dropped their price target on shares of Shattuck Labs from $31.00 to $21.00 and set a buy rating for the company in a research report on Friday, August 12th.

Shattuck Labs Price Performance

Shares of NASDAQ STTK opened at $3.25 on Wednesday. The stock has a market capitalization of $137.74 million, a price-to-earnings ratio of -2.23 and a beta of 0.92. The business has a 50-day moving average of $4.12 and a 200-day moving average of $4.04. Shattuck Labs has a fifty-two week low of $2.59 and a fifty-two week high of $22.62.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors have recently made changes to their positions in the stock. Prosight Management LP raised its holdings in shares of Shattuck Labs by 206.9% in the 1st quarter. Prosight Management LP now owns 798,718 shares of the company’s stock worth $3,403,000 after acquiring an additional 538,475 shares during the last quarter. Laurion Capital Management LP bought a new stake in Shattuck Labs in the 2nd quarter worth about $2,054,000. Clark Estates Inc. NY grew its position in Shattuck Labs by 52.9% in the 1st quarter. Clark Estates Inc. NY now owns 1,241,140 shares of the company’s stock worth $5,287,000 after purchasing an additional 429,500 shares in the last quarter. Cloverfields Capital Group LP grew its position in Shattuck Labs by 727.8% in the 4th quarter. Cloverfields Capital Group LP now owns 372,511 shares of the company’s stock worth $3,170,000 after purchasing an additional 327,511 shares in the last quarter. Finally, Millennium Management LLC grew its position in Shattuck Labs by 218.1% in the 2nd quarter. Millennium Management LLC now owns 264,025 shares of the company’s stock worth $1,072,000 after purchasing an additional 181,036 shares in the last quarter. Institutional investors and hedge funds own 50.59% of the company’s stock.

Shattuck Labs Company Profile

(Get Rating)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Featured Stories

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.